FAN Yue,WANG Yiming,FENG Quansheng.Experience in Treating Diarrhea-predominant Irritable Bowel Syndrome Based on the Theory of Spleen Deficiency Generating Turbidity[J].Journal of Traditional Chinese Medicine,2024,65(09):958-961.
FAN Yue,WANG Yiming,FENG Quansheng.Experience in Treating Diarrhea-predominant Irritable Bowel Syndrome Based on the Theory of Spleen Deficiency Generating Turbidity[J].Journal of Traditional Chinese Medicine,2024,65(09):958-961.DOI: 10.13288/j.11-2166/r.2024.09.015.
Based on the view of "spleen deficiency generating turbidity", it is believed that the main pathology of irritable bowel syndrome diarrhea-predominant (IBS-D) is spleen deficiency and turbidity excess, with spleen deficiency as the root and turbidity stagnating intestines as the branch, and the treatment principle of draining turbidity and transporting the center was proposed. In the acute stage, turbidity excess is the main cause, the treatment should unblock the bowels and discharge turbidity, commonly with modified
Zhishi Daozhi Decoction
(枳实导滞汤); in the remission stage, spleen deficiency is the main cause, the treatment should boost
qi
and fortify the spleen, commonly with modified
Qiwei Baizhu Powder
(七味白术散). Treating the branch in acute conditions, and treating the root in moderate conditions, so as to help restore the conduction function of the intestines and bowels, the transportation and transformation function of the spleen and stomach, then the water and grains have their own way, clear and turbid each in its own way.
关键词
Keywords
references
FORD AC , SPERBER AD , CORSETTI M , et al . Irritable bowel syndrome [J]. Lancet , 2020 , 396 ( 10263 ): 1675 - 1688 .
SPERBER AD , BANGDIWALA SI , DROSSMAN DA , et al . Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study [J]. Gastroenterology , 2021 , 160 ( 1 ): 99 - 114, e 3 .
LU Y , CHAI Y , QIU J , et al . Integrated omics analysis reveals the epigenetic mechanism of visceral hypersensiti-vity in IBS-D [J]. Front Pharmacol , 2023 , 14 : 1062630 . doi: 10.3389/fphar.2023.1062630 http://dx.doi.org/10.3389/fphar.2023.1062630 .